Lynda M McSorley, Mehala Tharmabala, Fathiya Al Rahbi, Fergus Keane, Denis Evoy, James G Geraghty, Jane Rothwell, Damian P McCartan, Megan Greally, Miriam O'Connor, Deirdre O'Mahony, Maccon Keane, Michael John Kennedy, Seamus O'Reilly, Steve J Millen, John P Crown, Catherine M Kelly, Ruth S Prichard, Cecily M Quinn, Janice M Walshe
Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational study was undertaken between 2011 and 2019 on a cross-section of hormone receptor-positive (HR+), HER2-negative, lymph node-negative, early-stage breast cancer patients. All patients had ILC and had RS testing in Ireland. The patient population is representative of the national population...
March 1, 2024: Current Oncology